Tradestie Institutional Equity Comparison Engine

AKAN vs NEXR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NEXR Overall Edge

NEXR Captures Institutional Edge (2โ€“1 Pillars ยท 1โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to NEXR (NEXR) driven by superior Momentum & Technical, Options & Structure while AKAN counters with relative strength in Growth & Margin. Fundamentally, AKAN trades at N/M Forward P/E with -1254.5% operating margin (+21.9% YoY revenue) versus NEXR at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, AKAN sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against NEXR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AKAN N/M vs NEXR N/M Fwd P/E
Growth & Margin Winner AKAN
Op Margin -1254.5% vs N/A ยท YoY +21.9% vs N/A
Momentum & Technical Winner NEXR
1Y +55.0% vs -39.2% ยท 52W Pos 2% vs 23%
Options & Structure Winner NEXR
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
AKAN NASDAQ
Akanda Corp. Common Shares
Medicinal Chemicals & Botanical Products
$2.00
+47.05% 1D
Market Cap $2.2M
1M Return +66.66%
1Y Return +55.03%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 20.0 Fund 60.0 Flow 50.0 Mom 70.0
NEXR US Equity
NEXR
Institutional Equity
$1.38
-7.38% 1D
Market Cap N/A
1M Return +67.27%
1Y Return -39.21%
Forward P/E N/M
Unified AI Score
31.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AKAN +55.03% NEXR -39.21% Spread: +225.77 pp (AKAN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AKAN TTM Op. Margin: -1254.5% NEXR TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKAN vs NEXR. Trailing 12-month operating profitability (AKAN -1254.5% vs NEXR N/A) and valuation multiples (AKAN N/M vs NEXR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AKAN (7) vs NEXR (1)
Institutional Metric AKAN NEXR Criterion Row Winner
Market Capitalization Scale $2.2M N/A Larger Scale AKAN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +21.9% N/A Higher Growth AKAN
Operating Margin (TTM) Profitability -1254.5% N/A Higher Margin AKAN
Net Profit Margin Profitability 0.0% N/A Higher Margin AKAN
Return on Equity (ROE) Capital Efficiency -60.9% N/A Higher ROE AKAN
52-Week Range Position Momentum 2% ($0โ€“$79) 23% ($0โ€“$5) Stronger Trend NEXR
Beta / 30D Volatility Risk Regime 5.43ฮฒ ยท 428% Vol 8.42ฮฒ ยท 2730% Vol Lower Realized Risk AKAN
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 31.0 / 100 (SELL) Higher Composite AKAN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AKAN vs NEXR Buy Guide
AKAN BREAKDOWN
137d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AKAN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NEXR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live NEXR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AKAN nor NEXR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.